Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy

HER2-positive breast cancers that achieve pathological complete response (pCR) after HER2-directed therapy consistently have good survival. We previously identified HSD17B4 methylation as a marker for pCR by methylation screening. Here, we aimed to identify a new marker by conducting a multi-omics a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Satoshi, Hattori, Naoko, Fujii, Satoshi, Yamaguchi, Takeshi, Takahashi, Masato, Hozumi, Yasuo, Kogawa, Takahiro, El-Omar, Omar, Liu, Yu-Yu, Arai, Nobuaki, Mori, Akiko, Higashimoto, Hiroko, Ushijima, Toshikazu, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511952/
https://www.ncbi.nlm.nih.gov/pubmed/32968149
http://dx.doi.org/10.1038/s41598-020-72661-9

Ejemplares similares

Ejemplares similares